http://www.zibb.com/all/theme/cq/Vertex+Pharmaceuticals+Incorporated Zibb. The Global business search engine. en-US search@zibb.com (RB Search)Copyright (c) 2007 Reed Business Information. All rights reserved.Mon, 23 Nov 2009 14:39:20 GMTMon, 23 Nov 2009 14:39:20 GMT608831http://www.zibb.com/all/theme/cq/Vertex+Pharmaceuticals+Incorporated http://www.zibb.com/images/en/g_zibb_logo_beta.gif http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3671468&HITNO=14&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=biotechnology%20pharmaceutical&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R%3adate&R=3671468&THISHREF=http%3a//c.moreover.com/click/here.pl%3fz2349056229%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBiotechnology and Pharmaceutical Industry Search Find Companies, News, Events, Jobs, Directoryhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3671468&HITNO=14&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=biotechnology%20pharmaceutical&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R%3adate&R=3671468&THISHREF=http%3a//c.moreover.com/click/here.pl%3fz2349056229%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comVertex Pharmaceuticals IncorporatedMon, 23 Nov 2009 14:39:20 GMThttp://finance.yahoo.com/news/Vertex-Pharmaceuticals-bw-2151277650.html?x=0&.v=1CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX - News) today announced that it will webcast its presentations at thehttp://finance.yahoo.com/news/Vertex-Pharmaceuticals-bw-2151277650.html?x=0&.v=1Vertex Pharmaceuticals IncorporatedFri, 20 Nov 2009 21:44:00 GMThttp://www.zibb.com/article/5684930/Vertex+Pharmaceuticals+Announces+Webcasts+of+its+Presentations+at+Two+Investor+ConferencesVertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentations at the Piper Jaffray 21st Annual Health Care Conference on Wednesday, December 2, 2009 at 2:00 p.m. EST and at the 2009 Deutsche Bank Biotech Boston Confab on Tuesday, December 15, 2009 at 9:00http://www.zibb.com/article/5684930/Vertex+Pharmaceuticals+Announces+Webcasts+of+its+Presentations+at+Two+Investor+ConferencesVertex Pharmaceuticals IncorporatedFri, 20 Nov 2009 16:44:00 GMThttp://www.newratings.com/en/main/company_headline.m?id=1979336NEW YORK, October 21 (newratings.com) - Analysts at Wedbush Morgan reinitiate coverage of Vertex Pharma (ticker: VRTX) with a "neutral" rating. The target price is set to $42. [more]http://www.newratings.com/en/main/company_headline.m?id=1979336Vertex Pharmaceuticals IncorporatedWed, 21 Oct 2009 21:15:32 GMThttp://biz.yahoo.com/bw/081126/20081126005061.html?.v=1Vertex Pharmaceuticals Announces Webcast of its Presentation at Two Investor Conferences. - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX - News) today announced that it will webcast its presentation at the Piper Jaffray 20th Annual Health Care Conference onhttp://biz.yahoo.com/bw/081126/20081126005061.html?.v=1Vertex Pharmaceuticals IncorporatedWed, 26 Nov 2008 14:15:00 GMThttp://www.fool.com/investing/high-growth/2008/11/10/5-star-stocks-poised-to-pop-viropharma.aspxThe Motley Fool - Market-trouncing returns could be written in this five-star stock.http://www.fool.com/investing/high-growth/2008/11/10/5-star-stocks-poised-to-pop-viropharma.aspxVertex Pharmaceuticals IncorporatedMon, 10 Nov 2008 23:46:30 GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/zacks/081028/15543.html?.v=1Vertex Pharma Promising, Volatile. - Vertex Pharmaceuticals Inc. (NasdaqGS: VRTX - News) primarily focuses on developing drugs in areas of viral diseases, inflammation, autoimmune diseases and cancer, either independently or in association with other pharmaceutical companies.http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/zacks/081028/15543.html?.v=1Vertex Pharmaceuticals IncorporatedTue, 28 Oct 2008 16:25:39 GMThttp://www.californiabiotechlaw.com/archives/-biotech-deals-fallout-continues-on-roche-bid-for-genentech.htmlDespite Genentech's rejection of Roche's $43.7 billion offer last week, coverage of the fallout from thefailedbidhttp://www.californiabiotechlaw.com/archives/-biotech-deals-fallout-continues-on-roche-bid-for-genentech.htmlVertex Pharmaceuticals IncorporatedMon, 18 Aug 2008 21:30:06 GMThttp://seekingalpha.com/article/90111-power-one-inc-q2-2008-earnings-call-transcript?source=yahooGood day ladies and gentlemen and welcome to the Power-One second quarter 2008 teleconference. At this time all participants are in a listen-only mode. We’ll facilitate a question-and-answer session towards the end of today’s conference.http://seekingalpha.com/article/90111-power-one-inc-q2-2008-earnings-call-transcript?source=yahooVertex Pharmaceuticals IncorporatedSat, 09 Aug 2008 15:38:12 GMThttp://www.bloomberg.com/apps/news?pid=20601087&sid=aD781WHCqrXA&refer=homeJuly 25 (Bloomberg) -- Genentech Inc., the biggest U.S. maker of cancer medicines, said it has formed a three-member board committee to review Roche Holding AG's $43.7 billion takeover bid.http://www.bloomberg.com/apps/news?pid=20601087&sid=aD781WHCqrXA&refer=homeVertex Pharmaceuticals IncorporatedFri, 25 Jul 2008 17:09:32 GMThttp://www.smartbrief.com/news/NRA/industryBW-detail.jsp?id=A2C059F1-1104-4FA6-89E3-2281FD6056C6&sb_code=RSS&i=FoodserviceSAS(R) for Clinical Data Integration Helps Reduce Time-to-Market for New Drugshttp://www.smartbrief.com/news/NRA/industryBW-detail.jsp?id=A2C059F1-1104-4FA6-89E3-2281FD6056C6&sb_code=RSS&i=FoodserviceVertex Pharmaceuticals IncorporatedMon, 23 Jun 2008 12:31:34 GMThttp://www.sas.com/news/preleases/062308/SASforClinicalDI.html?rss=sas.corp.us.pr1&utm_medium=RSS&utm_source=Corp_PressReleaseSAS® Clinical Data Integration Server will provide a new platform for life sciences organizations to define, manage, and automate their processes for aggregating medical data.http://www.sas.com/news/preleases/062308/SASforClinicalDI.html?rss=sas.corp.us.pr1&utm_medium=RSS&utm_source=Corp_PressReleaseVertex Pharmaceuticals IncorporatedMon, 23 Jun 2008 12:00:00 GMThttp://www.xconomy.com/2008/06/12/vertex-moves-hepatitis-drug-forward-merrimack-rakes-in-60m-biogen-and-icahn-trade-barbs-more-life-sciences-news/Much of the week's life sciences news was dominated by the bickering of Biogen Idec and billionaire investor Carl Icahn. A few other interesting thingshttp://www.xconomy.com/2008/06/12/vertex-moves-hepatitis-drug-forward-merrimack-rakes-in-60m-biogen-and-icahn-trade-barbs-more-life-sciences-news/Vertex Pharmaceuticals IncorporatedThu, 12 Jun 2008 04:01:25 GMThttp://www.marketwatch.com/news/story/story.aspx?guid=%7B6E8099FB%2D58DD%2D4049%2DA987%2D5C5BBC1F3581%7D&siteid=rssDrug stocks inch higher, with shares of Schering-Plough climbing as its polio drug compound begins testing.http://www.marketwatch.com/news/story/story.aspx?guid=%7B6E8099FB%2D58DD%2D4049%2DA987%2D5C5BBC1F3581%7D&siteid=rssVertex Pharmaceuticals IncorporatedTue, 03 Jun 2008 13:59:00 GMThttp://www.biospace.com/news_story.aspx?StoryID=98675&full=1CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX - News) today announced that it has sold its rights to future royalties in Lexiva and Agenerase under its 1993 license agreement with GlaxoSmithKline plc (GSK) in the field of HIV protease inhibitors for a one-timehttp://www.biospace.com/news_story.aspx?StoryID=98675&full=1Vertex Pharmaceuticals IncorporatedTue, 03 Jun 2008 12:00:00 GMThttp://hbswk.hbs.edu/item/5927.htmlHigh-stakes decision-making in the presence of an audience can bring out the worst in leaders. As HBS professor Deepak Malhotra and colleagues write in the May issue of Harvard Business Review , competitive arousalan adrenaline-fueled emotional state exacerbated by rivalry, timehttp://hbswk.hbs.edu/item/5927.htmlVertex Pharmaceuticals IncorporatedThu, 08 May 2008 02:00:00 GMThttp://www.cnbc.com/id/23900156/site/14081545?__source=yahoo|headline|quote|text|&par=yahooGiven investor reaction to the Vytorin/Zetia news yesterday, you might draw the conclusion the huge cholesterol drug franchise might be doomed. Sure, analysts say, prescriptions and sales are gonna go down some more, but they're not going to zero.http://www.cnbc.com/id/23900156/site/14081545?__source=yahoo|headline|quote|text|&par=yahooVertex Pharmaceuticals IncorporatedTue, 01 Apr 2008 15:03:45 GMThttp://news.moneycentral.msn.com/ticker/article.aspx?Feed=FOOL&Date=20081110&ID=9364094&Symbol=US:YHOOMotley Fool business news by ticker, 5-Star Stocks Poised to Pop: ViroPharma, Yahoo! Inc, US:YHOOhttp://news.moneycentral.msn.com/ticker/article.aspx?Feed=FOOL&Date=20081110&ID=9364094&Symbol=US:YHOOVertex Pharmaceuticals IncorporatedThu, 01 Jan 1970 00:00:00 GMThttp://www.prplace.com/pr_news/view/id-2093summary :(AP:CHICAGO--) (BUSINESS WIRE) _ Feb. 11 2009-- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and event ...http://www.prplace.com/pr_news/view/id-2093Vertex Pharmaceuticals Incorporatedhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=336143CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 12, 2009--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX), completed its acquisition today of ViroChem Pharma Inc., a privately-held company with two investigational HCV polymerase inhibitors in clinical development.http://www.pharmacychoice.com/News/article.cfm?Article_ID=336143Vertex Pharmaceuticals Incorporatedhttp://topics.nytimes.com/top/news/business/companies/vertex-pharmaceuticals-inc/index.htmlVertex Pharmaceuticals expects to receive $545 million in milestone payments, plus additional royalties, from Johnson & Johnson as part of agreement to market and develop VX-950, promising hepatitis C drughttp://topics.nytimes.com/top/news/business/companies/vertex-pharmaceuticals-inc/index.htmlVertex Pharmaceuticals Incorporatedhttp://www.npsp.com/news_releasetxt.php?ReqId=799876SALT LAKE CITY, Nov. 4 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP - News) today reported its operating and financial results for the three and nine months ended September 30, 2005 and reviewed recent corporate developments. Third Quarter Financial Resultshttp://www.npsp.com/news_releasetxt.php?ReqId=799876Vertex Pharmaceuticals Incorporatedhttp://www.holdrs.com/holdrs/main/index.asp?Action=Article&Description=&Image=&newsid={5C4D2DCA-2A71-43C5-A216-A6C46120C860}&symb=VRTX&sid=7853Joshua Boger, Ph.D., President and Chief Executive Officer of Vertex, will present at Deutsche Bank's 2008 Biotech Boston Confab. Vertex's presentation will be conducted on Tuesday, November 11, 2008 at 3:25 p.m. EST.http://www.holdrs.com/holdrs/main/index.asp?Action=Article&Description=&Image=&newsid={5C4D2DCA-2A71-43C5-A216-A6C46120C860}&symb=VRTX&sid=7853Vertex Pharmaceuticals Incorporatedhttp://pharmabioingredients.com/news/2006/12/11/merck_and_vertex_move_to_mid-stage_trialDrug makers Merck & Co. and Vertex Pharmaceuticals Inc. said Monday they will move on to a mid-stage clinical trial for their cancer treatment now that a dosing trial is complete.http://pharmabioingredients.com/news/2006/12/11/merck_and_vertex_move_to_mid-stage_trialVertex Pharmaceuticals Incorporatedhttp://www.zibb.com/article/5674901/Vertex+Pharmaceuticals+VRTX+Downgrade+Alert+Watch+for+Technical+Uptrend+ReversalVertex Pharmaceuticals (NASDAQ:VRTX) downgraded to Neutral from Buy, $32-39 target, at Merriman. The stock closed yesterday at $40.50 on volume of 2,560,800 shares, above average daily volume of 1,907,525. Vertex Pharmaceuticals is currently above its 50-day moving average of $35.99 and above itshttp://www.zibb.com/article/5674901/Vertex+Pharmaceuticals+VRTX+Downgrade+Alert+Watch+for+Technical+Uptrend+ReversalVertex Pharmaceuticals IncorporatedTue, 17 Nov 2009 09:31:07 GMT